A RWS of the FARAPULSE in A Chinese Population With PAF

The primary effectiveness endpoint is the acute procedural success, defined as the proportion of subjects that achieve electrical isolation of all PVs using FARAPULSE Pulsed Field Ablation system only.

The primary safety endpoint is defined as the occurrence of the acute serious procedure-related and /or device-related adverse events at 7 days post index procedure.

Primary endpoints analysis is planned to be conducted after all enrolled subjects have completed data collection at 1-month follow-up visit. All the subjects underwent study device treatment will be followed up to 12 months after the procedure, and the secondary and other endpoints will be analyzed then.

Inclusion criteria

• Subjects who are ≥ 18 and ≤ 75 years of age on the day of enrollment;
• Subjects whose preoperative diagnosis is PAF confirmed by the clinician;
• De novo ablation procedure for PAF with Class I or IIa recommendations* according to 2018 Chinese expert consensus on atrial fibrillation therapy;
• Subjects who are able and willing to provide the defined observational data and/or participate in baseline and follow-up evaluations for the full study;
• Subjects who are willing and capable of providing informed consent.

Exclusion criteria

• Subjects who, in the judgment of the investigator, have a life expectancy of less than one year before the procedure;
• Women of childbearing potential who are, or plan to become, pregnant during the time of the study;
• Subjects with any known contraindication to AF ablation with FARAPULSE Pulsed Field Ablation system, anticoagulation therapy, or contrast media in the judgment of the investigator or subjects unwillingness to use systemic anticoagulation
• Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study.